BC Innovations | Feb 27, 2014
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neuropathy Glial cell line-derived neurotrophic factor family receptor a1 (GFRA1) Studies in mice suggest a small molecule positive modulator of GFRA1...
BioCentury | Dec 13, 2010
Strategy

Unwinding Biovail's Deals

Unwinding Biovail's Deals Deal date Partner Product Product description Product status Deal status Deal terms Jun-10 Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) Istradefylline Adenosine A2A receptor (ADORA2A) antagonist FDA not approvable letter in 2008 for...
BC Week In Review | Nov 8, 2010
Clinical News

Glial derived neurotrophic factor: Development discontinued

Valeant said it will not pursue further development of preclinical candidate BVF-014 for PD. Valeant said the program, which it gained through its merger with Biovail Corp. this year, did not fit with the merged...
BC Innovations | Jan 28, 2010
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Glial cell-derived neurotrophic factor (GDNF); glial cell line-derived neurotrophic factor family receptor a1 (GFRA1); ret proto-oncogene (RET) Studies in mice suggest that inhibiting...
BC Week In Review | Feb 14, 2005
Clinical News

Glial derived neurotrophic factor: Phase II halted

AMGN stopped an open-label extension of a Phase II trial of 48 patients with advanced PD after new preclinical data showed that the compound caused irreversible cerebellar lesions in non-human primates. Data from the trial,...
BC Week In Review | Jul 5, 2004
Clinical News

Glial derived neurotrophic factor: Phase II data

AMGN said in a double-blind Phase II trial in 34 patients, GDNF failed to meet the primary endpoint at 6 months. Patients who received daily infusions of 15 mg of GDNF into the putamen region...
Items per page:
1 - 6 of 6